BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32767993)

  • 21. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
    Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J
    J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.
    van der Heide DM; Turaga KK; Chan CHF; Sherman SK
    J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers.
    Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N
    Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency.
    Yunlong W; Tongtong L; Hua Z
    Cancer Med; 2023 Feb; 12(3):2440-2452. PubMed ID: 35904113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study.
    Zhao L; Fu Y; Niu P; Zhang F; Jiao F; Zhou X; Wu Z; Wang W; Luan X; Han X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y
    Oncologist; 2023 Oct; 28(10):e891-e901. PubMed ID: 37104872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
    Rohr UP; Herrmann P; Ilm K; Zhang H; Lohmann S; Reiser A; Muranyi A; Smith J; Burock S; Osterland M; Leith K; Singh S; Brunhoeber P; Bowermaster R; Tie J; Christie M; Wong HL; Waring P; Shanmugam K; Gibbs P; Stein U
    Ann Oncol; 2017 Aug; 28(8):1869-1875. PubMed ID: 28460000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].
    Chen K; Liang H; Peng J; Zheng Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Nov; 38(11):1300-1305. PubMed ID: 30514676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LDH-A negatively regulates dMMR in colorectal cancer.
    Zhang Y; Li J; Wang B; Chen T; Chen Y; Ma W
    Cancer Sci; 2021 Aug; 112(8):3050-3063. PubMed ID: 34110068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
    Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
    World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis.
    Deng Z; Qin Y; Wang J; Wang G; Lang X; Jiang J; Xie K; Zhang W; Xu H; Shu Y; Zhang Y
    Clin Genet; 2020 Jan; 97(1):25-38. PubMed ID: 31432497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
    Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
    Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L;
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
    Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X
    Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
    Barrow P; Richman SD; Wallace AJ; Handley K; Hutchins GGA; Kerr D; Magill L; Evans DG; Gray R; Quirke P; Hill J
    Histopathology; 2019 Aug; 75(2):236-246. PubMed ID: 31062389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deficient mismatch repair as a prognostic marker in stage II colon cancer patients.
    Gkekas I; Novotny J; Fabian P; Nemecek R; Palmqvist R; Strigård K; Pecen L; Svoboda T; Gurlich R; Gunnarsson U
    Eur J Surg Oncol; 2019 Oct; 45(10):1854-1861. PubMed ID: 31186203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of age and mismatch repair status on survival in colorectal cancer.
    Li P; Xiao ZT; Braciak TA; Ou QJ; Chen G; Oduncu FS
    Cancer Med; 2017 May; 6(5):975-981. PubMed ID: 28345223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of novel models for predicting mismatch repair protein deficiency and relevant disease-free survival in colorectal cancer patients.
    Xu Y; Li Y; Zhu Z; Yang J; Tan Y; Wang Y; Xu X
    Int J Colorectal Dis; 2022 Jun; 37(6):1449-1464. PubMed ID: 35482069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy.
    Halldorsson MO; Hauptmann M; Snaebjornsson P; Haraldsdóttir KH; Aspelund T; Gudmundsson EF; Gudnason V; Jonasson JG; Haraldsdottir S
    Scand J Gastroenterol; 2018 Aug; 53(8):972-975. PubMed ID: 30010450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology.
    Vivaldi C; Genovesi V; Ugolini C; Bernardini L; Casadei-Gardini A; Formica V; Salani F; Orsi G; Massa V; Cacciato-Insilla A; Caccese M; Cesario S; Andrikou K; Graziani J; Campani D; Vasile E; Fontanini G; Fornaro L; Masi G
    Oncology; 2024; 102(2):157-167. PubMed ID: 37699372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.